$EXEL2025 · v5

Exelixis (EXEL): 13.4x EV/EBITDA and 14.6x EV/FCF Price a Mature Franchise Despite 35.0% ROIC and 33.2% FCF Growth

Interesting research candidate

67Signal score
2025Fiscal year
HealthcareSector
67Interesting research candidate
Report date
Friday, 12 June 2026
Company
Exelixis, Inc.
Sector
Healthcare
Industry
Biotechnology
Version
v5

Research PDF

signalshield-EXEL-2025-v5.pdf
Download PDF
⬇ Download full PDFDirect download. Opens in any PDF reader. Public archive report.

This report is provided for informational research support only. It does not constitute investment, financial, or trading advice.

← All research reports